biotech.today

Details

  • ●Modalities: small molecules
  • ●Therapeutic areas: inflammation, ALS
  • ●Key targets:
  • ●Indications: Undisclosed
  • ●Funding: $800M

Partners & investors

  • AstraZeneca· Investor

Key considerations

  • ●AI tools in use: Benevolent Platform
  • ●Euronext listing 2022
  • ●Baricitinib COVID-19 repurposing (2020 successful FDA EUA)
  • ●AstraZeneca $800M collaboration

Pipeline

  • Phase 21
Get live updates on BenevolentAI’s hiring, filings, and partnerships. Follow in BT Pro →
Source: Company website, SEC / Companies House filings, press releases, Crunchbase · biotech.today analysis (Apr 2026)

Key people

Joerg Moeller

CEO

biotech-leadership
Visit website →LinkedIn →